Vycor Medical, Inc. VYCO
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.81M | 1.89M | 1.86M | 1.90M | 1.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.81M | 1.89M | 1.86M | 1.90M | 1.78M |
| Cost of Revenue | 300.60K | 307.90K | 302.30K | 278.60K | 253.50K |
| Gross Profit | 1.51M | 1.58M | 1.56M | 1.62M | 1.53M |
| SG&A Expenses | 1.40M | 1.42M | 1.46M | 1.46M | 1.42M |
| Depreciation & Amortization | 58.70K | 58.70K | 59.60K | 59.60K | 59.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.76M | 1.79M | 1.83M | 1.81M | 1.76M |
| Operating Income | 48.30K | 92.50K | 33.90K | 89.70K | 22.50K |
| Income Before Tax | -56.40K | -11.60K | -70.20K | -14.50K | -79.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.06 | -0.01 | -0.07 | -0.01 | -0.08 |
| Earnings from Discontinued Operations | -3.60K | -2.20K | -2.20K | -2.00K | -1.90K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.00K | -13.80K | -72.50K | -16.50K | -81.20K |
| EBIT | 48.30K | 92.50K | 33.90K | 89.70K | 22.50K |
| EBITDA | 110.40K | 155.30K | 97.10K | 153.70K | 86.30K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 133.49M | 133.49M | 133.49M | 133.49M | 133.03M |
| Average Diluted Shares Outstanding | 133.49M | 138.79M | 138.79M | 138.79M | 138.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |